NMTC · Insider Trading
NeuroOne Medical Technologies Corporation Common Stock
Every open-market purchase and sale reported by NMTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | David J. Wambeke | Chief Business Officer | Buy | +33,333 | +$67.00K |
| 2026-08-28 | David A Rosa | CEO & President | A | +68,000 deriv. | — |
| 2026-08-28 | Christopher Volker | Chief Financial Officer | A | +35,000 deriv. | — |
| 2026-08-28 | Emily J. Johns | Chief Administrative Officer | A | +12,500 deriv. | — |
| 2026-08-28 | Mark Christianson | Market Development Director | A | +12,500 deriv. | — |
| 2026-08-28 | Steve Mertens | Chief Technology Officer | A | +15,000 deriv. | — |
| 2026-07-02 | Mark Christianson | Market Development Director | Sell | −10,000 | −$31.77K |
| 2026-04-07 | Jeffrey S Mathiesen | Director | A | +41,929 | — |
| 2026-04-07 | Edward Andrle | Director | A | +41,929 | — |
| 2026-04-07 | Jason Richard Mills | Director | A | +41,929 | — |
| 2026-04-07 | Paul Buckman | Director | A | +41,929 | — |
| 2026-04-01 | David A Rosa | CEO and President | F | −2,458 | −$1.91K |
| 2026-04-01 | Mark Christianson | Business Development Director | MIXED | −15,616 | −$11.57K |
| 2026-04-01 | Steve Mertens | Chief Technology Officer | F | −906 | −$704 |
| 2026-03-16 | Mark Christianson | Business Development Director | Sell | −917 | −$734 |
| 2026-03-12 | Mark Christianson | Business Development Director | Sell | −13,720 | −$10.98K |
| 2026-03-03 | David J. Wambeke | Chief Business Officer | Buy | +1,000,000 | +$670.40K |
| 2026-02-20 | Mark Christianson | Business Development Director | F | −1,812 | −$1.23K |
| 2026-02-20 | David A Rosa | CEO and President | F | −71,325 | −$48.50K |
| 2026-02-20 | Steve Mertens | Chief Technology Officer | F | −7,376 | −$5.02K |
| 2026-01-05 | Mark Christianson | Business Development Director | F | −253 | −$192 |
| 2026-01-05 | Steve Mertens | Chief Technology Officer | F | −906 | −$687 |
| 2026-01-05 | David A Rosa | CEO and President | F | +2,458 | +$1.86K |
| 2026-01-02 | Jason Richard Mills | Director | A | +7,758 | — |
| 2025-10-01 | David A Rosa | CEO and President | F | −2,458 | −$2.18K |
| 2025-10-01 | Mark Christianson | Business Development Director | F | −253 | −$225 |
| 2025-10-01 | Steve Mertens | Chief Technology Officer | F | −906 | −$805 |
| 2025-09-09 | Mark Christianson | Business Development Director | Sell | −30,000 | −$22.20K |
| 2025-07-02 | David A Rosa | CEO and President | F | −2,458 | −$1.67K |
| 2025-07-02 | Steve Mertens | Chief Technology Officer | F | −906 | −$614 |
| 2025-07-02 | Mark Christianson | Business Development Director | F | −253 | −$172 |
| 2025-06-25 | Jeffrey S Mathiesen | Director | A | +50,000 deriv. | — |
| 2025-06-25 | Paul Buckman | Director | A | +50,000 deriv. | — |
| 2025-06-25 | Edward Andrle | Director | A | +50,000 deriv. | — |
| 2025-06-05 | Mark Christianson | Business Development Director | Sell | −10,000 | −$5.80K |
| 2025-06-03 | Emily J. Johns | General Counsel | A | +500,000 deriv. | — |
| 2025-05-23 | Mark Christianson | Business Development Director | Sell | −8,981 | −$5.60K |
| 2025-05-21 | Mark Christianson | Business Development Director | Sell | −11,019 | −$7.31K |
| 2025-04-21 | Steve Mertens | Chief Technology Officer | A | +200,000 deriv. | — |
| 2025-04-21 | David A Rosa | CEO and President | A | +750,000 deriv. | — |
| 2025-04-21 | Ronald W. McClurg | Chief Financial Officer | A | +250,000 deriv. | — |
| 2025-04-21 | Christopher Volker | Chief Operating Officer | A | +575,000 deriv. | — |
| 2025-04-21 | Mark Christianson | Business Development Director | A | +200,000 deriv. | — |
| 2025-04-07 | Ronald W. McClurg | Chief Financial Officer | Buy | +200,000 | +$100.00K |
| 2025-04-07 | David A Rosa | CEO and President | Buy | +100,000 | +$50.00K |
| 2025-04-02 | David A Rosa | CEO and President | F | −2,458 | −$2.09K |
| 2025-04-02 | Mark Christianson | Business Development Director | F | −253 | −$215 |
| 2025-04-02 | Steve Mertens | Chief Technology Officer | F | −906 | −$770 |
| 2025-02-20 | David A Rosa | CEO and President | F | −71,325 | −$82.74K |
| 2025-02-20 | Steve Mertens | Chief Technology Officer | F | −7,376 | −$8.56K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David J. Wambeke | Chief Business Officer | 199,999 | $160.78K |
| David A Rosa | CEO & President | 180,022 | $144.72K |
| Ronald W. McClurg | Chief Financial Officer | 74,020 | $59.50K |
| Paul Buckman | Director | 29,789 | $23.95K |
| Jeffrey S Mathiesen | Director | 26,057 | $20.95K |
| Steve Mertens | Chief Technology Officer | 25,357 | $20.38K |
| Edward Andrle | Director | 22,322 | $17.94K |
| Mark Christianson | Market Development Director | 20,692 | $16.63K |
| Christopher Volker | Chief Financial Officer | 12,500 | $10.05K |
| Jason Richard Mills | Director | 8,281 | $6.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NMTC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.